Notícias

Bristol Myers Squibb's Growth Portfolio Just Hit $7.7 Billion. Is This Cheap Pharma Stock a No-Brainer Buy?

NASDAQ

Key PointsBristol Myers Squibb has an attractive 4.3% yield, and its P/E is below average for a drug maker.

Ler o briefing completo da Veytics

Mostramos publicamente o ponto principal. Crie uma conta gratuita para continuar lendo o artigo completo, salva-lo, comenta-lo e conecta-lo ao contexto de mercado e OSINT.